<code id='109BBD7120'></code><style id='109BBD7120'></style>
    • <acronym id='109BBD7120'></acronym>
      <center id='109BBD7120'><center id='109BBD7120'><tfoot id='109BBD7120'></tfoot></center><abbr id='109BBD7120'><dir id='109BBD7120'><tfoot id='109BBD7120'></tfoot><noframes id='109BBD7120'>

    • <optgroup id='109BBD7120'><strike id='109BBD7120'><sup id='109BBD7120'></sup></strike><code id='109BBD7120'></code></optgroup>
        1. <b id='109BBD7120'><label id='109BBD7120'><select id='109BBD7120'><dt id='109BBD7120'><span id='109BBD7120'></span></dt></select></label></b><u id='109BBD7120'></u>
          <i id='109BBD7120'><strike id='109BBD7120'><tt id='109BBD7120'><pre id='109BBD7120'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:7788
          Christine Kao/STAT

          There’s a specter haunting Wall Street.

          It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

          advertisement

          Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In